Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Background: Primary systemic amyloidosis (AL) is a multisystemic disorder resulting from an underlying plasma cell dyscrasia. There is no formal staging system for AL, making comparisons between studies and treatment centers difficult. Our group previously identified elevated serum cardiac troponin T (cTnT) as the most powerful predictor of overall survival. Others have reported that N-terminal pronatriuretic peptide (NT-proBNP) is a valuable prognostic marker. Objective: To develop a staging system for patients with AL. Methods: 242 patients with newly diagnosed AL seen at the Mayo Clinic between April 1979 and November 2000, who had echocardiograms and stored serum samples at presentation. NT-proBNP measurements were performed on 242 patients in whom cTnT and troponin I (cTnI) had been previously run; overall survival. Two prognostic models were designed using threshold values of NT-proBNP and either cTnT or cTnI (NT-proBNP < 332 ng/L, cTnT <0.035 µg/L and cTnI <0.1 µg/L). Depending on whether NT-proBNP and troponin levels were both low, both high, or only one high, patients were classified as Stage I, III, or II, respectively. Results: Using the cTnT/NT-proBNP model 33, 30, and 37% were Stages I, II, and III with median survivals of 26.4, 10.5, and 3.5 months, respectively. The alternate cTnI/NT-proBNP model predicted median survivals of 27.2, 11.1, and 4.1 months, respectively. Conclusions: Stratification of AL patients into 3 stages is possible with two readily available and reproducible tests setting the stage for more consistent and reliable cross comparisons of therapeutic outcomes. Supported in part by CA 62242(R.A.K), CA 91561(A.D) from the National Cancer Institute, and the Robert A. Kyle Hematology Malignancies Fund, Mayo Foundation.

Original languageEnglish (US)
Title of host publicationAmyloid and Amyloidosis
PublisherCRC Press
Pages67-69
Number of pages3
ISBN (Electronic)9781420037494
ISBN (Print)0849335345, 9780849335341
StatePublished - Jan 1 2004

Fingerprint

Troponin
Brain Natriuretic Peptide
Troponin T
Troponin I
Amyloidosis
Serum
Survival
Paraproteinemias
National Cancer Institute (U.S.)
Hematology
peptide A
pro-brain natriuretic peptide (1-76)
Primary amyloidosis
Peptides
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology and Microbiology(all)
  • Neuroscience(all)

Cite this

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide : A staging system for primary systemic amyloidosis. / Dispenzieri, Angela; Kyle, R. A.; Lacy, Martha; Jaffe, Allan S; Therneau, Terry M; Zeldenrust, S. R.; Gertz, Morie.

Amyloid and Amyloidosis. CRC Press, 2004. p. 67-69.

Research output: Chapter in Book/Report/Conference proceedingChapter

@inbook{5642cdec86cd47589b9b195f7ba1ed82,
title = "Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis",
abstract = "Background: Primary systemic amyloidosis (AL) is a multisystemic disorder resulting from an underlying plasma cell dyscrasia. There is no formal staging system for AL, making comparisons between studies and treatment centers difficult. Our group previously identified elevated serum cardiac troponin T (cTnT) as the most powerful predictor of overall survival. Others have reported that N-terminal pronatriuretic peptide (NT-proBNP) is a valuable prognostic marker. Objective: To develop a staging system for patients with AL. Methods: 242 patients with newly diagnosed AL seen at the Mayo Clinic between April 1979 and November 2000, who had echocardiograms and stored serum samples at presentation. NT-proBNP measurements were performed on 242 patients in whom cTnT and troponin I (cTnI) had been previously run; overall survival. Two prognostic models were designed using threshold values of NT-proBNP and either cTnT or cTnI (NT-proBNP < 332 ng/L, cTnT <0.035 µg/L and cTnI <0.1 µg/L). Depending on whether NT-proBNP and troponin levels were both low, both high, or only one high, patients were classified as Stage I, III, or II, respectively. Results: Using the cTnT/NT-proBNP model 33, 30, and 37{\%} were Stages I, II, and III with median survivals of 26.4, 10.5, and 3.5 months, respectively. The alternate cTnI/NT-proBNP model predicted median survivals of 27.2, 11.1, and 4.1 months, respectively. Conclusions: Stratification of AL patients into 3 stages is possible with two readily available and reproducible tests setting the stage for more consistent and reliable cross comparisons of therapeutic outcomes. Supported in part by CA 62242(R.A.K), CA 91561(A.D) from the National Cancer Institute, and the Robert A. Kyle Hematology Malignancies Fund, Mayo Foundation.",
author = "Angela Dispenzieri and Kyle, {R. A.} and Martha Lacy and Jaffe, {Allan S} and Therneau, {Terry M} and Zeldenrust, {S. R.} and Morie Gertz",
year = "2004",
month = "1",
day = "1",
language = "English (US)",
isbn = "0849335345",
pages = "67--69",
booktitle = "Amyloid and Amyloidosis",
publisher = "CRC Press",

}

TY - CHAP

T1 - Serum cardiac troponins and N-terminal pro-brain natriuretic peptide

T2 - A staging system for primary systemic amyloidosis

AU - Dispenzieri, Angela

AU - Kyle, R. A.

AU - Lacy, Martha

AU - Jaffe, Allan S

AU - Therneau, Terry M

AU - Zeldenrust, S. R.

AU - Gertz, Morie

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Background: Primary systemic amyloidosis (AL) is a multisystemic disorder resulting from an underlying plasma cell dyscrasia. There is no formal staging system for AL, making comparisons between studies and treatment centers difficult. Our group previously identified elevated serum cardiac troponin T (cTnT) as the most powerful predictor of overall survival. Others have reported that N-terminal pronatriuretic peptide (NT-proBNP) is a valuable prognostic marker. Objective: To develop a staging system for patients with AL. Methods: 242 patients with newly diagnosed AL seen at the Mayo Clinic between April 1979 and November 2000, who had echocardiograms and stored serum samples at presentation. NT-proBNP measurements were performed on 242 patients in whom cTnT and troponin I (cTnI) had been previously run; overall survival. Two prognostic models were designed using threshold values of NT-proBNP and either cTnT or cTnI (NT-proBNP < 332 ng/L, cTnT <0.035 µg/L and cTnI <0.1 µg/L). Depending on whether NT-proBNP and troponin levels were both low, both high, or only one high, patients were classified as Stage I, III, or II, respectively. Results: Using the cTnT/NT-proBNP model 33, 30, and 37% were Stages I, II, and III with median survivals of 26.4, 10.5, and 3.5 months, respectively. The alternate cTnI/NT-proBNP model predicted median survivals of 27.2, 11.1, and 4.1 months, respectively. Conclusions: Stratification of AL patients into 3 stages is possible with two readily available and reproducible tests setting the stage for more consistent and reliable cross comparisons of therapeutic outcomes. Supported in part by CA 62242(R.A.K), CA 91561(A.D) from the National Cancer Institute, and the Robert A. Kyle Hematology Malignancies Fund, Mayo Foundation.

AB - Background: Primary systemic amyloidosis (AL) is a multisystemic disorder resulting from an underlying plasma cell dyscrasia. There is no formal staging system for AL, making comparisons between studies and treatment centers difficult. Our group previously identified elevated serum cardiac troponin T (cTnT) as the most powerful predictor of overall survival. Others have reported that N-terminal pronatriuretic peptide (NT-proBNP) is a valuable prognostic marker. Objective: To develop a staging system for patients with AL. Methods: 242 patients with newly diagnosed AL seen at the Mayo Clinic between April 1979 and November 2000, who had echocardiograms and stored serum samples at presentation. NT-proBNP measurements were performed on 242 patients in whom cTnT and troponin I (cTnI) had been previously run; overall survival. Two prognostic models were designed using threshold values of NT-proBNP and either cTnT or cTnI (NT-proBNP < 332 ng/L, cTnT <0.035 µg/L and cTnI <0.1 µg/L). Depending on whether NT-proBNP and troponin levels were both low, both high, or only one high, patients were classified as Stage I, III, or II, respectively. Results: Using the cTnT/NT-proBNP model 33, 30, and 37% were Stages I, II, and III with median survivals of 26.4, 10.5, and 3.5 months, respectively. The alternate cTnI/NT-proBNP model predicted median survivals of 27.2, 11.1, and 4.1 months, respectively. Conclusions: Stratification of AL patients into 3 stages is possible with two readily available and reproducible tests setting the stage for more consistent and reliable cross comparisons of therapeutic outcomes. Supported in part by CA 62242(R.A.K), CA 91561(A.D) from the National Cancer Institute, and the Robert A. Kyle Hematology Malignancies Fund, Mayo Foundation.

UR - http://www.scopus.com/inward/record.url?scp=85057699393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057699393&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:85057699393

SN - 0849335345

SN - 9780849335341

SP - 67

EP - 69

BT - Amyloid and Amyloidosis

PB - CRC Press

ER -